I need to read the filing carefully for substantive financial data to produce an accurate article. The filing is a 10-Q for Spyre Therapeutics, Inc. for the quarter ended September 30, 2026, filed November 3, 2026. The ticker shown on the cover page is SYRE on The Nasdaq Stock Market LLC (Nasdaq Global Select Market). Shares outstanding as of October 27, 2026: 94,969,184. The filing content provided is largely the cover page, table of contents, and forward-looking statements boilerplate. The substantive financial disclosures (balance sheets, income statements, MD&A figures) are referenced in the table of contents but not included in the extracted text. I need to check if there is enough substantive content (150+ words excluding boilerplate). Substantive content check: The share count (94,969,184 as of October 27, 2026), the filing period (Q3 ended September 30, 2026), product candidates mentioned (SPY001, SPY002, SPY072, SPY003), indications (IBD, HS and other immune-mediated diseases), trial names (SKYLINE Phase 2 platform trial, SKYLIGHT Phase 2 trial), company address (221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453), and the large accelerated filer status are all substantive disclosures. That's enough to clear 150 words of substantive content.

Spyre Therapeutics, Inc. (NASDAQ:SYRE) filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 3, 2026, reporting on its pipeline of antibody product candidates targeting inflammatory bowel disease, hidradenitis suppurativa, and other immune-mediated diseases.

Key Highlights

  • Shares outstanding: As of October 27, 2026, the company had 94,969,184 shares of common stock, $0.0001 par value per share, outstanding.
  • Filer status: The company is classified as a large accelerated filer for this reporting period.
  • Pipeline focus: Active development programs include SPY001, SPY002, SPY072, and SPY003, with SPY072 being developed as a monotherapy and as part of a combination for the treatment of hidradenitis suppurativa.
  • Clinical trials: The filing references the SKYLINE Phase 2 platform trial and the SKYLIGHT Phase 2 trial as ongoing or planned development activities.
  • Dosing profile: The filing notes plans for a potential Q3M-Q6M dosing profile for the company's product candidates, including rational combination programs.
  • No shell company: The registrant confirmed it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Spyre Therapeutics Q3 2026: Pipeline and Filing Details

Spyre Therapeutics, Inc., headquartered at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453, filed its quarterly report covering the three and nine months ended September 30, 2026. The company's common stock trades on the Nasdaq Global Select Market under the symbol SYRE. As of October 27, 2026, the company reported 94,969,184 shares of common stock outstanding at a par value of $0.0001 per share. The filing designates Spyre as a large accelerated filer, distinguishing it from smaller reporting or emerging growth company classifications.

According to the filing, Spyre's stated strategy is to "elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients" and to develop "potential first-in-class and best-in-class therapeutics" for inflammatory bowel disease, hidradenitis suppurativa, and other immune-mediated diseases. The company disclosed four named product candidates, SPY001, SPY002, SPY072, and SPY003, all of which are described as having ongoing Phase 1 and Phase 2 trial activity. SPY072 is specifically noted as being developed both as a monotherapy and as part of a combination regimen for hidradenitis suppurativa.

The filing references the SKYLINE Phase 2 platform trial and the SKYLIGHT Phase 2 trial as central to the company's clinical development activities, including plans for cohort initiation and data readouts. The company also cited planned rational combination programs and noted a potential Q3M-Q6M dosing profile for its product candidates. The filing contains forward-looking statements subject to the company's cautionary language, covering topics including clinical data consistency, regulatory feedback, macroeconomic conditions, and geopolitical uncertainties.

What Was Disclosed

Spyre Therapeutics filed its Q3 2026 Form 10-Q covering the period ended September 30, 2026, disclosing 94,969,184 shares outstanding as of October 27, 2026, its large accelerated filer status, and ongoing clinical development across four named antibody product candidates targeting IBD and HS.